Read More

Lexaria Bioscience Reports First Phase Of Its Epilepsy Research Program Begun This Week; DehydraTECH-CBD Test Articles Have Been Manufactured, Delivered To Third-Party Lab Engaged To Complete Research

Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing.